Characterization of early pathogenesis in the SOD1G93A mouse model of ALS: part II, results and discussion

被引:135
|
作者
Vinsant, Sharon [1 ,2 ]
Mansfield, Carol [1 ,2 ]
Jimenez-Moreno, Ramon [1 ,2 ]
Moore, Victoria Del Gaizo [3 ]
Yoshikawa, Masaaki [1 ,2 ]
Hampton, Thomas G. [4 ]
Prevette, David [1 ,2 ]
Caress, James [5 ,6 ]
Oppenheim, Ronald W. [1 ,2 ]
Milligan, Carol [1 ,2 ]
机构
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurobiol & Anat, Neurosci Program, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, ALS Ctr, Winston Salem, NC 27157 USA
[3] Elon Univ, Dept Chem, Elon, NC USA
[4] Mouse Specif, Boston, MA USA
[5] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27157 USA
[6] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27157 USA
来源
BRAIN AND BEHAVIOR | 2013年 / 3卷 / 04期
基金
美国国家卫生研究院;
关键词
Axons; cytoplasmic vacuoles; glia; mega-mitochondria; mitochondria; motoneurons; motor function; NM[!text type='Js']Js[!/text; AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; CU; ZN SUPEROXIDE-DISMUTASE; AXONAL-TRANSPORT DEFECTS; PROGRAMMED CELL-DEATH; C RNA VIRUS; SPINAL-CORD; GOLGI-APPARATUS; TRANSGENIC MICE; MITOCHONDRIAL DYSFUNCTION;
D O I
10.1002/brb3.142
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Pathological events are well characterized in amyotrophic lateral sclerosis (ALS) mouse models, but review of the literature fails to identify a specific initiating event that precipitates disease pathology. There is now growing consensus in the field that axon and synapses are first cellular sites of degeneration, but controversy exists over whether axon and synapse loss is initiated autonomously at those sites or by pathology in the cell body, in nonneuronal cells or even in nonmotoneurons (MNs). Previous studies have identified pathological events in the mutant superoxide dismutase 1 (SOD1) models involving spinal cord, peripheral axons, neuromuscular junctions (NMJs), or muscle; however, few studies have systematically examined pathogenesis at multiple sites in the same study. We have performed ultrastructural examination of both central and peripheral components of the neuromuscular system in the SOD1 G93A mouse model of ALS. Twenty percent of MNs undergo degeneration by P60, but NMJ innervation in fast fatigable muscles is reduced by 40% by P30. Gait alterations and muscle weakness were also found at P30. There was no change in axonal transport prior to initial NMJ denervation. Mitochondrial morphological changes are observed at P7 and become more prominent with disease progression. At P30 there was a significant decrease in excitatory axo-dendritic and axo-somatic synapses with an increase in C-type axo-somatic synapses. Our study examined early pathology in both peripheral and central neuromuscular system. The muscle denervation is associated with functional motor deficits and begins during the first postnatal month in SOD1 G93A mice. Physiological dysfunction and pathology in the mitochondria of synapses and MN soma and dendrites occur, and disease onset in these animals begins more than 2 months earlier than originally thought. This information may be valuable for designing preclinical trials that are more likely to impact disease onset and progression.
引用
收藏
页码:431 / 457
页数:27
相关论文
共 50 条
  • [41] Intrathecal administration of a novel siRNA modality extends survival and improves motor function in the SOD1G93A ALS mouse model
    Duan, Chunling
    Kang, Moorim
    Pan, Xiaojie
    Gan, Zubao
    Huang, Vera
    Li, Guanlin
    Place, Robert F.
    Li, Long-Cheng
    MOLECULAR THERAPY NUCLEIC ACIDS, 2024, 35 (01):
  • [42] EXOCYTOSIS AND MITOCHONDRIAL ULTRASTRUCTURE AND FUNCTION IN CHROMAFFIN CELLS OF THE SOD1G93A MOUSE MODEL OF ALS AT A PRE-DISEASE STAGE
    Mendez-Lopez, I
    Martinez-Ramirez, C.
    Prieto Simancas, P.
    Ronda del Corro, M.
    Saez Albendea, L.
    Villaverde Rebenaque, P.
    Garcia, A. G.
    Padin Nogueira, J. F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 34 - 34
  • [43] Verapamil Ameliorates Motor Neuron Degeneration and Improves Lifespan in the SOD1G93A Mouse Model of ALS by Enhancing Autophagic Flux
    Zhang, Xiaojie
    Chen, Sheng
    Lu, Kaili
    Wang, Feng
    Deng, Jiangshan
    Xu, Zhouwei
    Wang, Xiuzhe
    Zhou, Qinming
    Le, Weidong
    Zhao, Yuwu
    AGING AND DISEASE, 2019, 10 (06): : 1159 - 1173
  • [44] Retinal glial changes in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis
    Ramirez, A. I.
    Salobrar-Garcia, E.
    Matamoros, J. A.
    Rojas, P.
    Fernandez Albarral, J. A.
    Lopez-Cuenca, I.
    Sanchez-Puebla, L.
    Elvira-Hurtado, L.
    Santos-Garcia, I.
    de lago, E.
    Ramirez, J. M.
    de Hoz, R.
    Salazar, J. J.
    GLIA, 2023, 71 : E443 - E444
  • [45] Erythropoietin modulates the immune-inflammatory response of a SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis (ALS)
    Noh, Min Young
    Cho, Kyung Ah
    Kim, Heejaung
    Kim, Sung-Min
    Kim, Seung Hyun
    NEUROSCIENCE LETTERS, 2014, 574 : 53 - 58
  • [46] Cortical Neurotoxic Astrocytes with Early ALS Pathology and miR-146a Deficit Replicate Gliosis Markers of Symptomatic SOD1G93A Mouse Model
    Cátia Gomes
    Carolina Cunha
    Filipe Nascimento
    Joaquim A. Ribeiro
    Ana Rita Vaz
    Dora Brites
    Molecular Neurobiology, 2019, 56 : 2137 - 2158
  • [47] Effects of the GPR17 antagonist montelukast on oligodendrocyte dysfunction and disease outcome in the SOD1G93A mouse model of ALS
    Bonifacino, T.
    Raffaele, S.
    Nguyen, N.
    Milanese, M.
    Bonanno, G.
    Abbracchio, M. P.
    Fumagalli, M.
    GLIA, 2021, 69 : E202 - E202
  • [48] Cortical Neurotoxic Astrocytes with Early ALS Pathology and miR-146a Deficit Replicate Gliosis Markers of Symptomatic SOD1G93A Mouse Model
    Gomes, Catia
    Cunha, Carolina
    Nascimento, Filipe
    Ribeiro, Joaquim A.
    Vaz, Ana Rita
    Brites, Dora
    MOLECULAR NEUROBIOLOGY, 2019, 56 (03) : 2137 - 2158
  • [49] Optimised and Rapid Pre-clinical Screening in the SOD1G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (ALS)
    Mead, Richard J.
    Bennett, Ellen J.
    Kennerley, Aneurin J.
    Sharp, Paul
    Sunyach, Claire
    Kasher, Paul
    Berwick, Jason
    Pettmann, Brigitte
    Battaglia, Guiseppe
    Azzouz, Mimoun
    Grierson, Andrew
    Shaw, Pamela J.
    PLOS ONE, 2011, 6 (08):
  • [50] Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS
    Kalmar, Bernadett
    Novoselov, Sergey
    Gray, Anna
    Cheetham, Michael E.
    Margulis, Boris
    Greensmith, Linda
    JOURNAL OF NEUROCHEMISTRY, 2008, 107 (02) : 339 - 350